Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aurinia Pharmaceuticals Inc. AUPH
$10.69
-$0.28 (-2.64%)
На 18:00, 12 мая 2023
+55.94%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1564906387.00000000
-
week52high
13.42
-
week52low
4.07
-
Revenue
134030000
-
P/E TTM
-15
-
Beta
1.17854600
-
EPS
-0.76000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 09 авг 2022 г. |
| Oppenheimer | Outperform | Outperform | 08 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 05 мая 2022 г. |
| RBC Capital | Outperform | Outperform | 28 апр 2022 г. |
| SVB Leerink | Outperform | Outperform | 08 мар 2022 г. |
| SVB Leerink | Outperform | Outperform | 04 ноя 2022 г. |
| RBC Capital | Outperform | Outperform | 04 ноя 2022 г. |
| Oppenheimer | Perform | Outperform | 04 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 ноя 2022 г. |
| RBC Capital | Outperform | Outperform | 04 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Donley Matthew Maxwell | A | 27927 | 10000 | 21 ноя 2022 г. |
| Habig Scott Michael | A | 5000 | 5000 | 09 ноя 2022 г. |
| Martin Michael Robert | A | 89512 | 30000 | 07 ноя 2022 г. |
| Habig Scott Michael | A | 137531 | 137531 | 01 авг 2022 г. |
| Habig Scott Michael | A | 231203 | 231203 | 01 авг 2022 г. |
| Knappertz Volker | A | 152812 | 152812 | 01 авг 2022 г. |
| Knappertz Volker | A | 256892 | 256892 | 01 авг 2022 г. |
| Jayne David R.W. | D | 0 | 10000 | 18 мая 2022 г. |
| Jayne David R.W. | A | 40000 | 10000 | 18 мая 2022 г. |
| MILNE GEORGE M JR | A | 14612 | 14612 | 18 мая 2022 г. |
Новостная лента
Here's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to Buy
Zacks Investment Research
11 мая 2023 г. в 13:44
Does Aurinia Pharmaceuticals (AUPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 13:08
Start Time: 08:30 January 1, 0000 9:27 AM ET Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Peter Greenleaf - President and CEO Joe Miller - CFO Jamie Harrell - Head of IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Farzin Haque - Jefferies Stacy Ku - TD Cowen Justin Kim - Oppenheimer Ed Arce - H.C. Wainwright David Martin - Bloom Burton Will Soghikian - SVB Securities Sahil Dhingra - RBC Capital Markets Operator Greetings, and welcome to Aurinia Pharmaceuticals Inc. First Quarter 2023 Earnings Call.
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 08:22
Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago.
3 Biotechs That Might Get Bought Out in 2023
The Motley Fool
26 апр 2023 г. в 11:30
With multiple blockbuster drugs going off patent this decade, pharma companies are expected to ratchet up their M&A activities. These three companies sport high-value assets that could attract suitors soon.
Aurinia Pharmaceuticals shareholder says sale could reward investors with nearly 200% gain
Proactive Investors
24 апр 2023 г. в 16:04
MKT Capital, which owns a 4.2% stake in Aurinia Pharmaceuticals (TSX:AUP) Inc, wrote in a letter to shareholders on Monday that the company should put itself up for sale, believing the biopharmaceutical firm could be worth up to $28 per share, equivalent to a 192% premium to its current stock price. MKT, meanwhile, expressed its disappointment in decisions made by the current board, especially the compensation committee's 2020 decision to reward CEO Peter Greenleaf with a $10.7 million pay package despite the poor performance of Aurinia's stock price.